*Research Article*

# **SURVEILLANCE OF CARBAPENEM-RESISTANT GRAM-NEGATIVE BACTERIA FROM ANIMAL SOURCES IN MATHURA REGION, UTTAR PRADESH, INDIA**

A. Arun<sup>1</sup>, U. Jaiswal<sup>1</sup>, S. Tripathi<sup>1</sup>, A. P. Singh<sup>1\*</sup>, S. Choudhury<sup>2</sup>, S. N. Prabhu<sup>3</sup>

*Received 05 February 2022, revised 11 June 2022*

**ABSTRACT: A cross-sectional study was conducted to determine the prevalence of Carbapenem-resistant Gram-negative bacteria (CR-GNB) in animals. The study involves one hundred eighty-four GNB isolates from 214 samples (faeces, milk, pus, and uterine discharge) from Buffalo (N=112), Cattle (N=50) and, Dog (N=52). Healthy and diseased animals reported to Veterinary Clinical Complex were sampled. Carbapenemase production was evaluated by phenotypic methods and presence of metallo** β**-lactamase genes was assayed by PCR. We observed a 9.78% overall prevalence of CR-GNB in animal sources. CR-GNB was more frequently recovered from companion animals (19.23%) when compared to livestock (4.93%). IMP (44.4%), VIM (38.8%), and OXA-48 (16.66 %) were the main MBLs observed in the study.**

**Key words:** Gram-negative bacteria, Carbapenem, Antibiotic resistance, Animals.

## **INTRODUCTION**

Carbapenems are a beta-lactam class of antibiotics. Carbapenems are stable to most beta-lactamase enzymes mediated inactivation unlike other beta-lactam antibiotics (Perrott *et al.* 2010). Carbapenems are clinicians' preferred choice for the therapeutic management of serious infections caused by MDR pathogens (Falagas and Karageorgopoulos 2009). The ever-growing dependence has led to the recent emergence of carbapenem-resistant bacterial strains. Genes encoding carbapenem-resistance are often associated with mobile genetic elements leading to their spread across a variety of carbapenem-resistant Gram-negative bacteria (CR-GNB) (Schwaber *et al.* 2011).

Most clinically relevant carbapenem resistance appears to have arisen and propagated because of its therapeutic uses in humans (Poirel *et al.* 2014). CR-GNB has been isolated predominantly from humans and environmental samples. Presently, carbapenems are not authorized for use in veterinary medicine in most parts of the world; hence carbapenem resistance is not common in GNB isolated from animals. Notwithstanding, CR-GNB has been detected in livestock, companion animals, and their environment by several workers across the globe in the recent past (Wang *et al.* 2012, Woodford *et al.* 2014). The overall carriage rate of CR-GNB has been on the rise in food-producing animals and their environment in India (Ghatak *et al.* 2013, Pruthvishree *et al.* 2017, Nirupama *et al.* 2018). The colonization of CR-GNB in livestock and companion animals has a potential multiplier effect on rapid dissemination to humans through close contact, environmental and, food-borne transmission. The prevalence of CR-GNB has risen significantly in animal healthcare settings over the past few years, but the data on the population prevalence among livestock and pet animals are scanty in India. Therefore, it is necessary to include CR-GNB for routine epidemiological investigations in animal population. The present study aimed to predict the population prevalence of CR-GNB from various animal sources and their characterization.

## **MATERIALS AND METHODS Bacterial Isolates**

The carbapenem resistance surveillance includes 214 GNB samples (faces, milk, pus, and uterine discharge)

*1 Department of Veterinary Microbiology, 2 Department of Veterinary Pharmacology & Toxicology, 3 Department of Veterinary Pathology, College of Veterinary Science and Animal Husbandry, U.P. Pandit Deen Dayal Upadhyayay Pashu Chikitsa Vigyan Vishwavidhyalaya Ewam Gau Anusandhan Sansthan, Mathura, U.P., India.*

\**Corresponding author. e-mail: drajay\_vet@yahoo.co.in*

collected between during May 2018 and April 2021 from separate animals in and around the Mathura region, India, without any inclusion or exclusion criteria. Sample details given in Table 1. A total of 184 GNB were isolated, and further identified by the standard microbiological procedure (Barrow and Feltham 2004). Control strain includes *Klebsiella pneumoniae* ATCC BAA 1705+KPC and *Klebsiella pneumoniae* ATCC BAA 1706.

#### **Antibiotic susceptibility test**

Antimicrobial susceptibility analysis was carried out by standard Kirby-Bauer disk diffusion method using Mueller-Hinton agar (Sigma-Aldrich) following the CLSI (2017) guidelines and interpretative criteria (Table S2).



**Fig. 1. Representative results obtained by Modified Carba NP test.** [b,c,d] represents results obtained by imipenem- non susceptible strain where 'A' tube (red colour/control tube) is a negative and tube 'B' (yellow colour) is a positive result *i.e.,* carbapenemase-producing isolate. [a & e] represents results obtained by imipenem-susceptible strain where both tubes (A,B) are negative results *i.e*., carbapenemase-non producing isolate. (a) Negative Control *E. coli* ATCC 25922 (b) Positive Control *Klebsiella pneumoniae* ATCC BAA 1705 [1b] Representative results obtained by mCIM: CIA (-) represents negative result of ertapenem susceptible strain *i.e.,* zone = 20 mm and CIA (-) represents positive result of ertapenem nonsusceptible strain *i.e.,* no zone of inhibition around the carbapenem disk. *E. coli* ATCC 25922 has been used as reporter strain. [1c] Representative results obtained by Modified hodge test: Isolates VA-41 and VA-52 were Modified Hodge Test Negative, while isolates VA-19 was Modified Hodge Test Positive.





The panel of antimicrobial agents consisted of 10 different antimicrobial-impregnated disks: namely, ertapenem (10 µG), cefotaxime (30 µG), ceftazidime (30 µG), gentamicin (10  $\mu$ G), ampicillin (10  $\mu$ G), amoxicillinclavulanate (10 $\mu$ g), ciprofloxacin (5  $\mu$ g), cefoxitin (30  $\mu$ g), ceftriaxone (30  $\mu$ g) and cefpodoxime (10  $\mu$ g). The zone of inhibition was measured in mm and interpreted as sensitive, intermediate, or resistant.

#### **Minimum inhibitory concentration (MIC)**

The minimum inhibitory concentrations (MICs) of carbepenems (imipenem, ertapenem and meropenem) were tested by the broth microdilution method (Wiegand *et al.* 2008). Standardized bacterial inoculums were prepared for each isolate to give a turbidity equivalent to that of a 0.5 McFarland standard corresponding to 1 X108 cfu/ml. The final test concentration of the bacteria was achieved by further diluting the adjusted suspension by a factor of 1:100 to achieve approximately  $5 \times 10^5$  cfu/ ml. The working antibiotic stock solution was prepared by 1:10 dilution of antibiotic stock solution (potency adjusted 1.28 mg/ml) in Muller Hinton Broth (MHB). The plates were covered by sterile covers and incubated at 37ºC for 18-24 h. The lowest concentration of the antibiotics that did not have visible bacterial growth was defined as the MIC.

## **Phenotypic and genotypic carbapenemase identification**

Carbapenemase activity was assessed by modified Carba NP test (Rudresh *et al.* 2017), Carbapenemase Inactivation Assay (Zwaluw *et al.* 2015) and Modified Hodge test (Amjad *et al.* 2011). For genotypic detection, DNA isolated by the snap chill method was subjected to a target amplification of β-Lactamase genes using a panel



**Fig. 2. [a] PCR amplification of blaOXA48: 281 bp, blaIMP: 139bp, Lane M: 100 bp DNA Ladder, Lane 1-9: Test Isolates [b] PCR amplification of blaVIM : 390 bp , Lane M: 100 bp DNA Ladder, Lane 1-8: Test Isolates.**

of primers for detection of OXA-48, KPC, VIM, IMP, and NDM genes by multiplex PCR (Dallenne *et al.* 2010). A 25 µl reaction mixture containing 12.5 µl Dream Taq Master Mix, variable number of primers and 2 µl of isolated DNA template was used. Amplification was carried involving initial denaturation at 94°C for 10 min and 30 cycles of denaturation at 94°C for the 40s, annealing at  $55^{\circ}$ C for 40s, and extension at  $72^{\circ}$ C for 1 min followed by final elongation step at  $72^{\circ}$ C for 7 min. A. The primer concentration and amplification conditioned for the PCR reactions were used as per the Table 1.

## **RESULTS AND DISCUSSION**

Between May 2018 and April 2021, we processed 214 non-repeated samples comprised of faces, milk, uterine swab, and pus. A total of 184 GNB isolates were obtained on a MacConkey agar plate. A total of 18 CR-GNB isolates including *Escherichia coli* (n=12), *Klebsiella pneumoniae* (n=2), *Citrobacter freundii* (n=2), *Enterobacter cloacae* (n=1), and *Pseudomonas aeruginosa* (n=1) showed reduced susceptibility to ertapenem, based on zone interpretative criteria. The carbapenem resistance has been reported in *E. coli* (Zhang *et al.* 2013), *Klebsiella pneumonia* (Diab *et al.* 2017), *Enterobacter*, *Citrobacter* (Mollenkopf *et al.* 2017). MIC of 18 CR-GNB isolates for imipenem, meropenem, and ertapenem was shown in Table 2. MIC of 18 CR-GNB isolates for imipenem, meropenem, and ertapenem were detected in the range of  $0.625 \mu g/ml$  to  $64 \mu g/ml$ ,  $0.0625$ µg/ml to 1 µg/ml, and 0.312 to 16 µg/ml, respectively (Table 2). None of the CR-GNB isolates were resistant to meropenem. All the isolates exhibited resistance to amoxicillin-clavulanate, while various resistance rates were observed for ceftazidime (83.3 %), cefotaxime (75 %), ceftriaxone (88.8 %), cefpodoxime (94.44 %), and ciprofloxacin (91.6 %). The least frequent resistances were against gentamicin (33.3%).

Out of eighteen carbapenem non-susceptible isolates, thirteen (72.22 %) showed a positive reaction in the carbapenemase biochemical test (Fig. 1) while PCR-based identification revealed the presence of one or more carbapenemase (IMP, VIM, and Oxa-48) in 12 isolates (66.66%). Molecular testing showed the presence of IMP, VIM, and OXA-48 MBLs in eight (44.44%), seven (38.88%), and three isolates (16.66%), respectively (Fig. 2, Table 2). All three OXA-48 bearing isolates were



**Fig. 3. Distribution of CRE-GNB isolates from various sample sources.**



Exploratory Animal and Medical Research, Vol.12, Issue 1, June, 2022 **Table 2. Details on the tests performed using different carbapenam suspected isolates.**

(AMC: Amoxicillin–Clavulanic acid, CPD: Cefpodoxime; AMP**:** Ampicillin, CAZ**:** Ceftazidime, CRO: Ceftriaxone, CIP: Ciprofloxacin, CTX: Cefotaxime, FOX: Cefoxitin, GM: Gentamicin, ETP: Ertapenem).

<b>Total GNB isolates</b>	<b>Livestock</b>	<b>Companion</b> Animal	
	<b>Buffalo</b>	Cattle	Dog
	$(n=112)$	$(n=50)$	$(n=52)$
Carbapenem resistant	4	4	10
<b>GNB</b>	$(3.57\%)$	$(8.00\%)$	(19.23%)

**Table 3. Number (% ) of Carbapenem resistant isolates from animal source.**

recovered from dogs. Three out of 18 isolates carried both VIM and IMP, while the co-existence of IMP and OXA-48 was found in one isolate. Previous reports suggest rare prevalence of VIM and Oxa-48 carbapenemase genes from bacterial strains of animal sources in India, however, recent report indicate more frequent occurrence of OXA-48, VIM and IMP genotype from fecal sample of the piglets, calves and dogs (Nirupama *et al.* 2018, Murugan *et al.* 2019, Sankar *et al.* 2021). The carbapenemase genes variants (KPC and



#### **Table S1. Primers used in PCR analysis.**

**Table S2. AST Zone diameters for control strain** *Escherichia coli* **(ATCC®25922™) and the test isolates used in this assay (PSAST 2017).**

<b>Antibiotic</b>	Disc code	<b>Antibiotic</b> concentration $(\mu$ g)	<b>Control</b> strain zone diameter diameter (mm)	<b>Control</b> observed (mm)	Test zone diameters (mm)		
						<b>Resistant Intermediate Susceptible</b>	
Amoxicillin &	$AMC-30$	20/10	18-24	22	$\leq$ =13	$14 - 17$	$>=18$
Clavulanic acid							
Ampicillin	AM	10	$16 - 22$	20	$\leq$ =13	$14 - 16$	$>=17$
Cefotaxime	$CTX-30$	30	29-35	34	$\leq$ =14	$15 - 22$	$>=23$
Ceftazidime	$CAZ-30$	30	$25 - 32$	29	$\leq$ 14	$15-17$	$>=18$
Cefpodoxime	$CPD-10$	10	$23 - 28$	25	$\leq$ 17	$18 - 20$	$>=21$
Ceftriazone	$CRO-30$	30	29-35	29	$\leq$ =13	$14 - 20$	$>=21$
Cefoxitin	$FOX-30$	30	$23 - 29$	24	$\leq$ =14	$15 - 17$	$>=18$
Ciprofloxacin	$CIP-5$	5	$30-40$	30	$\leq$ =15	$16 - 20$	$>=21$
Gentamicin	$GM-10$	10	$19-26$	17	$\leq$ 12	$13 - 14$	$>=15$
Ertapenem	$ETP-10$	10	29-36	32	$\leq$ 15	$16-18$	$>=19$

NDM) widely known for their rapid acquisition and dissemination, were not found.

The prevalence of CRE in different species of animals was recorded. Based on the results described herein, CR-GNB appears to be having a significant prevalence (9.78 %) in cattle and dogs. The earlier studies showed the varied incidence of CR-GNB ranging from 0.5 % to 25 % in different parts of the world. In the current study, we found slightly higher prevalence rates of CR-GNB in animals, than the rates reported by other researchers (Stolle *et al.* 2013, Saheen *et al.* 2013, Reynolds *et al.* 2019). In absence of strict regulatory framework governing the use of antimicrobials in animal production system and irrational therapeutic usage of antibiotics in veterinary practices in India, may have contributed for higher prevalence of CR-GNB in animals. The recovery of CR-GNB from cattle and dogs indicates a potential future public health crisis (Abraham *et al.* 2014). We recorded a higher prevalence of CR-GNB in dogs (19.23%) in comparison to bovine (4.93%) (Table 3). A significantly higher prevalence of CRE among companion animals observed in our study is in agreement with previous findings of Kock *et al* (2018) who inferred higher prevalence rate (1-15%) among livestock and companion animals in Asia.

We observed faecal samples 7.70% (14/184) were the major source of CRE isolates followed by uterine samples 2.17% (4/184) (Fig. 3). Traditionally, bovine excrements are used for mud-flooring, as manure in agricultural farmland, and dung cake preparation in villages in India. Human exposure to antibiotic-resistant bacteria present in bovine excrements poses a health risk. The colonization of CR-GNB in the animal gut microbiome is a concern since it could be readily transmitted to pet owners, veterinarians, farmers through close physical contact and may result in community spread. The frequent use of betalactams selects and maintains CR-GNB within the animal population. The prevalence of CR-GNB in faecal samples of dogs has been widely reported (González-Torralba *et al.* 2016, Gentilini *et al.* 2018). The faecal carriage of CR-GNB in dogs indicates the possible occurrence of interspecies transmission between humans and companion animals within the same household. Industrialization and urban expansion of Indian cities have resulted in an exponential rise in the stray dog population in urban and peri-urban areas. Humans can be exposed to CR-GNB through soil contaminated with stray-dog faeces in densely populated urban neighbourhoods inhabited by the low socio-income group.

#### **CONCLUSION**

The recovery of CR-GNB from livestock and companion animals has significant public health ramifications and this may be related to illegal carbapenem use in veterinary practice. The dissemination of carbapenem-resistant bacteria in livestock and the environment potentially has a far-reaching effect. Evidence of such transmission is the cause of concern for public health experts and warrants strict vigil to limit the species spillover cross-species transmission. Hence continuous surveillance for antimicrobial-resistant must include screening for CR-GNB in livestock and companion animals.

## **ACKNOWLEDGMENT**

The authors are also thankful to Vice-chancellor, U.P. Pandit Deen Dayal Upadhyayay Pashu Chikitsa Vigyan Vishwavidhyalaya Ewam Gau Anusandhan Sansthan Mathura, 281001 (U.P.), for providing infrastructural facility to review this study.

#### **REFERENCES**

Abraham S, Wong HS, Turnidge J, Johnson JR, Trott DJ (2014) Carbapenemase-producing bacteria in companion animals: a public health concern on the horizon. J Antimicrob Chemother 69(5): 1155-1157.

Amjad A, Mirza IA, Abbasi SA, Farwa U, Malik N, Zia F (2011) Modified Hodge test: A simple and effective test for detection of carbapenemase production. Iran J Microbiol 3(4): 189-193.

Barrow G, Feltham RKA (2004) Cowan and Steel's manual for identification of medical bacteria. 3rd. edn. Cambridge University Press, Cambridge 331.

CLSI (2017) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, approved standard, 9<sup>th</sup> edn. CLSI document M07-A9. Clinical and Laboratory Standards Institute, 950, West Valley Road, Pennsylvania 19087, USA.

Dallenne C, Da Costa A, Decré D, Favier C, Arlet G (2010) Development of a set of multiplex PCR assays for the detection of genes encoding important β-lactamases in Enterobacteriaceae. J Antimicrob Chemother 65(3): 490-495.

Diab M, Hamze M, Bonnet R, Saras E, Madec JY, Haenni M (2017) OXA-48 and CTX-M-15 extended-spectrum betalactamases in raw milk in Lebanon: epidemic spread of dominant *Klebsiella pneumoniae* clones. J Med Microbiol 66(11): 1688-1691.

Falagas ME, Karageorgopoulos DE (2009) Extendedspectrum β-lactamase-producing organisms. J Hosp Infect 73(4): 345-354.

Gentilini F, Turba ME, Pasquali F, Mion D, Romagnoli N *et al.* (2018) Hospitalized pets as a source of carbapenemresistance. Front Microbiol 6: 2872.

Ghatak S, Singha A, Sen A, Guha C, Ahuja A *et al.* (2013) Detection of New Delhi-metallo -beta -lactamase and extendedspectrum beta-lactamase genes in *Escherichia coli* isolated from mastitic milk samples. Transbound Emerg Dis 60: 385-389.

González-Torralba A, Oteo J, Asenjo A, Bautista V, Fuentes E, Alos JI (2016) Survey of carbapenemase-producing Enterobacteriaceae in companion dogs in Madrid, Spain. Antimicrob Agents Chemother 60(4): 2499-2501.

Köck R, Daniels-Haardt I, Becker K, Mellmann A, Friedrich AW *et al.* (2018) Carbapenem-resistant Enterobacteriaceae in wildlife, food-producing, and companion animals: a systematic review. Clinical Microbiol Infect 24: 1241-1250.

Mollenkopf DF, Stull JW, Mathys DA, Bowman AS, Feicht SM *et al.* (2017) Carbapenemase-producing Enterobacteriaceae recovered from the environment of a swine farrow-to-finish operation in the United States. Antimicrob Agents Chemother 61: 1298-1216.

Murugan MS, Sinha DK, Kumar OV, Yadav AK, Pruthvishree BS *et al.* (2019) Epidemiology of carbapenemresistant *Escherichia coli* and first report of blaVIM carbapenemases gene in calves from India. Epidemiol Infect 147: 1-5.

Nirupama KR, Vinodh Kumar OR, Pruthvishree BS, Sinha DK, Murugan MS *et al.* (2018) Molecular characterization of blaOXA-48 carbapenemase, extended-spectrum β-lactamase and Shiga toxin-producing *Escherichia coli* isolated from farm piglets in India. J Glob Antimicrob Resist 13: 201-205.

Poirel L, Berçot B, Millemann Y, Bonnin RA, Pannaux G, Nordmann P (2012) Carbapenemase-producing *Acinetobacter* spp. in cattle, France. Emerg Infect Dis 18(3): 523-525.

Pruthvishree BS, Vinodh Kumar OR, Sinha DK, Malik YP, Dubal ZB *et al.* (2017) Spatial molecular epidemiology of carbapenem-resistant and New Delhi metallo beta-lactamase (bla NDM)-producing *Escherichia coli* in the piglets of organized farms in India. J Appl Microbiol 122: 1537-1546.

Perrott J, Mabasa VH, Ensom MH (2010) Comparing outcomes of meropenem administration strategies based on pharmacokinetic and pharmacodynamic principles: a qualitative systematic review. Ann Pharmacother 44(3): 557-564.

PSAST (2017) Performance Standards for Antimicrobial Susceptibility Testing (M100),  $27<sup>th</sup>$  edn., Published by Clinical and Laboratory Standards Institute, (CLSI 2017), Pennsylvania, USA.

Reynolds ME, Phan HT, George S, Hubbard AT, Stoesser N *et al.* (2019) Occurrence and characterization of *Escherichia coli* ST410 co-harbouring bla NDM-5, bla CMY-42 and blaTEM-190 in a dog from the UK. J Antimicrob Chemother 74(5): 1207-1211.

Rudresh SM, Ravi GS, Sunitha L, Hajira SN, Kalaiarasan E, Harish BN (2017) Simple, rapid, and cost-effective modified Carba NP test for carbapenemase detection among Gramnegative bacteria. J Lab Physicians 9(04): 303-307.

Sankar S, Thresia AB, Mini M (2021) Molecular detection of Carbapenem resistant Gram-negative bacterial isolates from Dogs. Indian J Ani Res. DOI: 10 18805/IJAR.B-4297.

Shaheen BW, Nayak R, Boothe DM (2013) Emergence of a New Delhi metallo-β-lactamase (NDM-1)-encoding gene in clinical *Escherichia coli* isolates recovered from companion animals in the United States. Antimicrob Agents Chemother 57(6): 2902-2903.

Stolle I, Prenger-Berninghoff E, Stamm I, Scheufen S, Hassdenteufel E *et al.* (2013) Emergence of OXA-48 carbapenemase-producing *Escherichia coli* and *Klebsiella pneumoniae* in dogs. J Antimicrob Chemother 68(12): 2802- 2808.

Schwaber MJ, Lev B, Israeli A, Solter E, Smollan G *et al.* (2011) Containment of a country-wide outbreak of carbapenemresistant *Klebsiella pneumoniae* in Israeli hospitals via a nationally implemented intervention. Arch Clin Infect Dis 52(7): 848-855.

Wang Y, Wu C, Zhang Q, Qi J, Liu H, Wang Y *et al.* (2012) Identification of New Delhi metallo-β-lactamase 1 in *Acinetobacter lwoffii* of food animal origin. PLoS One 7(5):1- 6.

Wiegand I, Hilpert K, Hancock RE (2008) Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances. Nat Protoc 3(2): 163-175.

Woodford N, Wareham DW, Guerra B, Teale C (2014) Carbapenemase-producing Enterobacteriaceae and non-Enterobacteriaceae from animals and the environment: an emerging public health risk of our own making? J Antimicrob Chemother 69(2): 287-291.

Zhang WJ, Lu Z, Schwarz S, Zhang RM, Wang XM *et al.* (2013) Complete sequence of the blaNDM-1-carrying plasmid pNDM-AB from *Acinetobacter baumannii* of food animal origin. J Antimicrob Chemother 68: 1681-1682.

Zwaluw K, Haan A de, Pluister G, Bootsma H *et al.* (2015) The carbapenem inactivation method (CIM), a simple and lowcost alternative for the carba NP test to assess phenotypic carbapenemase activity in Gram-negative rods. PLoS One 10(3): 1-13.

**\*Cite this article as:** Arun A, Jaiswal U, Tripathi S, Singh AP, Choudhury S, Prabhu SN (2022) Surveillance of carbapenem-resistant Gram-negative bacteria from animal sources in Mathura region, Uttar Pradesh, India. Explor Anim Med Res 12(1): 91-98. DOI: 10.52635/eamr/ 12.1.91-98.